Ligand Pharmaceuticals
LGND
362 hedge funds and large institutions have $3.65B invested in Ligand Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 156 increasing their positions, 92 reducing their positions, and 84 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 92
12.04% more ownership
Funds ownership: 114.4% → 126.44% (+12%)
6% less funds holding
Funds holding: 385 → 362 (-23)
25% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 84
28% less call options, than puts
Call options by funds: $106M | Put options by funds: $147M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
45% less capital invested
Capital invested by funds: $6.66B → $3.65B (-$3.01B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$124M |
| 2 |
Millennium Management
New York
|
+$77M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$45.3M |
| 4 |
Jennison Associates
New York
|
+$32.8M |
| 5 |
Two Sigma Investments
New York
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$99.9M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$71.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$53.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.4M |
LGND Hedge Fund Activity: Q4 2018 in Review
362 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2018, worth a combined $3.65B — down 45% from $6.66B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of LGND and 63 opened new positions — a net loss of 21 holders — while 92 trimmed existing stakes and 156 added.
The largest buyer was Renaissance Technologies, adding an estimated $124M. The largest seller was BlackRock, cutting an estimated $99.9M.
- 362 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2018, down from 385 in Q3 2018.
- Funds reported $3.65B of Ligand Pharmaceuticals stock for Q4 2018, down 45% quarter-over-quarter.
- 63 funds opened new Ligand Pharmaceuticals positions in Q4 2018 and 84 closed out, a net change of -21 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2018 was Renaissance Technologies, an estimated $124M added.
- The largest Ligand Pharmaceuticals seller in Q4 2018 was BlackRock, an estimated $99.9M sold.
Based on aggregated 13F filings for Q4 2018.